Findings of two large phase III clinical trials first presented in 2020 showed a new HIV prevention injection to be highly effective. Yet, experts expect that the injection will only reach clinics in late 2022 or early 2023. If the rhetoric about bringing the urgency of COVID-19 to HIV is to mean anything, these timelines should be made shorter.
An antiretroviral injection administered every two months has been shown to be highly effective in preventing people from getting HIV in two large trials. Catherine Tomlinson asks what needs to happen before these injections become available to people in South Africa.
One of the most vibrant areas of HIV research these days is the search for new, more convenient ways to use antiretroviral medicines (ARVs) to prevent HIV infection. Elri Voigt rounds up the HIV pre-exposure prophylaxis (PrEP) research presented at the recent International AIDS Society Conference, including a biodegradable antiretroviral implant.
Early results from a pivotal trial of an HIV prevention injection announced by the University of the Witwatersrand researchers on Tuesday have been hailed as being a “game-changer” to turn “the tide on HIV” as it effectively reduces HIV acquisition and provides women more choices in how to protect themselves. Amy Green reports.
A recent announcement about a vaginal ring to prevent HIV has AIDS activists and women’s sexual and reproductive health advocates excited. But where would this ring fit in South Africa’s HIV prevention programme? Amy Green investigates.